Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.

Anagnostou VK, Brahmer JR.

Clin Cancer Res. 2015 Mar 1;21(5):976-84. doi: 10.1158/1078-0432.CCR-14-1187. Review.

2.

A longitudinal, collaborative, practice-based learning and improvement model to improve post-discharge heart failure outcomes.

Anagnostou VK, Bailey G, Sze E, Hay S, Hyson A, Federman DG.

Conn Med. 2014 Jan;78(1):33-6.

PMID:
24600779
3.

Programmed death ligand-1 expression in non-small cell lung cancer.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL.

Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.

4.

Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis.

Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC.

Eur J Endocrinol. 2012 Mar;166(3):373-81. doi: 10.1530/EJE-11-0838. Epub 2011 Oct 24. Review.

PMID:
22023791
5.

Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay.

Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL.

Cancer. 2012 Mar 15;118(6):1607-18. doi: 10.1002/cncr.26450. Epub 2011 Aug 25.

6.

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M.

Clin Cancer Res. 2011 Mar 1;17(5):1147-59. doi: 10.1158/1078-0432.CCR-10-1869. Epub 2011 Jan 10.

7.

Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients.

Anagnostou VK, Tiniakos DG, Fotinou M, Achimastos A, Syrigos KN.

Virchows Arch. 2011 Mar;458(3):331-40. doi: 10.1007/s00428-010-1015-4. Epub 2010 Dec 14.

PMID:
21161269
8.

Modeling prognostic factors in resectable pancreatic adenocarcinomas.

Botsis T, Anagnostou VK, Hartvigsen G, Hripcsak G, Weng C.

Cancer Inform. 2010 Jan 20;7:281-91.

9.

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN.

BMC Cancer. 2010 May 9;10:186. doi: 10.1186/1471-2407-10-186.

10.

Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.

Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD.

Am J Obstet Gynecol. 2010 Aug;203(2):162.e1-8. doi: 10.1016/j.ajog.2010.02.056. Epub 2010 Apr 24.

11.

Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?

Anagnostou VK, Lowery FJ, Syrigos KN, Cagle PT, Rimm DL.

Arch Pathol Lab Med. 2010 Apr;134(4):613-9. doi: 10.1043/1543-2165-134.4.613.

PMID:
20367312
12.

Analytic variability in immunohistochemistry biomarker studies.

Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91. doi: 10.1158/1055-9965.EPI-10-0097. Epub 2010 Mar 23.

13.
14.

High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma.

Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL.

Clin Cancer Res. 2009 Jun 15;15(12):4157-64. doi: 10.1158/1078-0432.CCR-09-0099. Epub 2009 Jun 9.

15.

Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.

Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL.

J Clin Oncol. 2009 Jan 10;27(2):271-8. doi: 10.1200/JCO.2008.17.0043. Epub 2008 Dec 8.

PMID:
19064983
16.

Right sited renal cell carcinoma metastasizing to the contralateral ovary: case report and review of the literature.

Anagnostou VK, Tiniakos DG, Chorti M, Kiagia M, Tourkantonis I, Alamara C, Syrigos KN.

Pathol Oncol Res. 2009 Mar;15(1):123-7. doi: 10.1007/s12253-008-9039-7. Epub 2008 May 21.

PMID:
18493874
17.

Ontogeny of intrinsic innervation in the human thymus and spleen.

Anagnostou VK, Doussis-Anagnostopoulou I, Tiniakos DG, Karandrea D, Agapitos E, Karakitsos P, Kittas C.

J Histochem Cytochem. 2007 Aug;55(8):813-20. Epub 2007 Apr 16.

PMID:
17438351

Supplemental Content

Loading ...
Support Center